57 research outputs found

    The emergence of the circulating vaccine-derived poliovirus type 2 in multiple countries requires active surveillance : current scenario and counteracting strategies

    Get PDF
    Dear Editor, On April 11, 2022, a child less than two years old living in the Tamanrasset province of South Algeria showed signs of acute flaccid paralysis (AFP). On July 8, 2022, this was notified by the WHO through the Global Polio Laboratory Network (GPLN) as a case of circulating vaccine-derived poliovirus type 2 (cVDPV2) [1]. In the past few months, several genetically-linked Sabin-like type 2 (SL-2) poliovirus isolates have been detected numerous times in the US and the UK [2]. Since last February, the GPLN in London has been consistently detecting SL-2 isolates in sewage samples. The latter showed enough mutations to be classified as type 2 vaccine-derived poliovirus (VDPV2) and, due to the evidence of community transmission, were classified as circulating VDPV2 (cVDPV2) [2]. No human cases of VDPV2 have been documented in the UK as of September 5, 2022. Only one case of VDPV2 was reported in an unvaccinated paralytic individual. This was the first poliomyelitis case reported in that country since 2013 that was not linked to recent international travel. In the US, the virus isolates detected in environmental samples were found to be genetically-related to those reported in the sewage samples from London and those from Jerusalem, Israel [2]. In the case of the child who showed AFP in Algeria, the cVDPV2 isolates were detected in the stool samples. This was the first case of cVDPV2 in that country. Genome sequencing showed that the isolated virus was genetically-related to one strain previously isolated in Kano, Nigeria. The child had not received the polio vaccine and had never travelled outside the Tamanrasset province. Public health investigations are currently underway in that region to identify any more AFP cases [1]

    Answer to September 2019 Photo Quiz

    No full text

    COVID-19 Era and the Constantly Reemerging Novel SARS-CoV-2 Variants Calls for Special Attention for the Geriatrics: A Real Challenge

    No full text
    Global public health is significantly challenged due to the continuing COrona VIrus Disease 2019 (COVID-19) outbreak brought forth by the severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) [...

    Presepsin: A Novel and Potential Diagnostic Biomarker for Sepsis

    No full text
    Abstract Sepsis is a potential clinical condition which is a consequence of infectious disease or a severe inflammatory reaction secondary to infection or injury. Sepsis in Greek means putrefaction or decay, correlating well with the multiple organ failure and severe shock resulting in death of the patient suffering from severe sepsis. Clinical management of sepsis requires prompt laboratory diagnosis and formulation of effective patient management strategies that may include antimicrobial chemotherapy in case of sepsis induced by infectious microbe. Although many laboratory biomarkers are available for the diagnosis of sepsis, only few markers have proven to be beneficial in differentiating infectious disease sepsis and sepsis of non-infectious origin. Of the available markers only few have prognostic value. We in this review discuss the utility of a novel and emerging sepsis marker, the presepsin which has a better diagnostic and prognostic value, and has been effective in predicting the survival of the sepsis patients
    corecore